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Abstract The aim of this study was to characterize the
interaction between 1-methyl-1,2,3,4-tetrahydroisoquino-
line (1-MeTHIQ—an endogenous parkinsonism-preventing
substance) and various antiepileptic drugs [AEDs: clona-
zepam (CZP), ethosuximide (ETS), gabapentin (GBP),
levetiracetam (LEV), tiagabine (TGB) and vigabatrin
(VGB)] in the mouse maximal electroshock (MES)-
induced seizure model. Results indicate that 1-MeTHIQ in
combination with CZP (at the fixed ratios of 50:1 and
25:1), ETS (1:10) and GBP (1:1, 1:2, 1:5 and 1:10) exerted
supra-additive (synergistic) interactions in the mouse MES
model. In contrast, 1-MeTHIQ in combination with CZP
(200:1 and 100:1), ETS (1:1, 1:2 and 1:5), LEV and VGB
(1:1, 1:2, 1:5 and 1:10), and TGB (200:1, 100:1, 50:1 and
25:1) produced additive interaction in the mouse MES
model. Total brain AED concentrations were unaffected by
1-MeTHIQ, and inversely, CZP, ETS and GBP had no
impact on total brain concentrations of 1-MeTHIQ, indi-
cating pharmacodynamic nature of synergistic interactions
between 1-MeTHIQ and the tested AEDs in the mouse
MES model. In conclusion, the supra-additive interactions
of 1-MeTHIQ with CZP (at the fixed ratios of 50:1 and
25:1), ETS (1:10) and GBP (1:1, 1:2, 1:5 and 1:10) in the
mouse MES model appear to be particularly favorable
combinations from a clinical viewpoint. The additive
combinations of 1-MeTHIQ with CZP (100:1, 50:1), ETS
(1:1, 1:2 and 1:5), LEV and VGB (1:1, 1:2, 1:5, and 1:10),
and TGB (200:1, 100:1, 50:1 and 25:1) seem to be neutral
and worthy of consideration in further clinical practice.
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present in the human and rodent brains as a mixture
of stereospecific (R)- and (S)-1-MeTHIQ enantiomers
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(Antkiewicz-Michaluk et al. 2011). The racemate (R,S)-1-
MeTHIQ, exhibits neuroprotective activity and plays a
crucial physiological role in the mammalian brain as an
endogenous regulator of dopaminergic activity (Ant-
kiewicz-Michaluk et al. 2001, 2003, 2004, 2011).
1-MeTHIQ is an endogenous amine synthesized enzymat-
ically by 1-MeTHIQ-ase (a membrane-bound protein)
localized in the mitochondrial—synaptosomal fraction
(Yamakawa and Ohta 1997; Yamakawa et al. 1999). This
naturally occurring substance displayed neuroprotective




(Antkiewicz-Michaluk et al. 2003, 2004; Kotake et al.
1995, 1996, 2005; Tasaki et al. 1991; Yamakawa and Ohta
1997, 1999; Yamakawa et al. 1999).
A large body of evidence suggests that 1-MeTHIQ
offers a unique and complex mechanism of neuroprotec-
tion, in which antagonism to the glutamatergic system
may play a very important role, suggesting a potential of
1-MeTHIQ as a therapeutic agent in various neurodegen-
erative disorders of the central nervous system (Ant-
kiewicz-Michaluk et al. 2006). In vitro studies have
revealed that 1-MeTHIQ antagonized a rise in brain
dopamine metabolism and glutamate release in frontal
cortex (Pietraszek et al. 2009). 1-MeTHIQ shares neuro-
protective abilities with established uncompetitive NMDA
receptor antagonists, which indirectly suggests that the
inhibitory effect of 1-MeTHIQ on NMDA receptors plays
a key role in its anti-excitotoxic activity and 1-MeTHIQ-
evoked neuroprotection seems to be evoked by induction
of neuronal tolerance to excitotoxicity (Kuszczyk et al.
2010).
Recently, 1-MeTHIQ has been examined as a potential
anticonvulsant agent in one of the experimental models of
primarily generalized seizures, the maximal electroshock
(MES)-induced seizure model in mice (Luszczki et al.
2006a, 2009, 2010). The MES-induced seizures are thought
to be an experimental model of tonic–clonic seizures and,
to a certain extent, of partial convulsions with or without
secondary generalization in man (Lo¨scher et al. 1991;
Lo¨scher 2002). Results obtained previously indicate that
1-MeTHIQ elevated the threshold for electroconvulsions in
mice (Luszczki et al. 2006a), and exerted the anticonvul-
sant action in mice at times ranging between 5 and 120 min
after its systemic (i.p.) administration (Luszczki et al.
2009). Additionally, 1-MeTHIQ enhanced the protective
action of carbamazepine (CBZ) and valproate (VPA), but
not that of phenobarbital (PB) or phenytoin (PHT) against
MES-induced seizures in mice (Luszczki et al. 2006a).
Moreover, the isobolographic analysis of interaction
revealed that 1-MeTHIQ synergistically interacted with PB
and exerted the additive interaction when concomitantly
administered with CBZ, PHT and VPA in the mouse MES
model (Luszczki et al. 2009). With type I isobolographic
analysis, the combination of 1-MeTHIQ with topiramate
(TPM) exerted supra-additive (synergistic) interaction,
whereas the combination of 1-MeTHIQ with oxcarbaze-
pine (OXC), lamotrigine (LTG) and pregabalin (PGB)
produced additive interaction in the mouse MES model
(Luszczki et al. 2010). Generally, the second-generation
antiepileptic drugs (AEDs) are known to possess a wider
spectrum of anticonvulsant activity, lower risk of side
effects or toxicity in comparison to classical AEDs, which
definitely predispose this group of drugs to more advanced
experimental and clinical studies.
In the present study, we decided to continue the exper-
iments using 1-MeTHIQ in combination with six various
AEDs: clonazepam (CZP), ethosuximide (ETS), gabapen-
tin (GBP), levetiracetam (LEV), tiagabine (TGB) and
vigabatrin (VGB) in the mouse MES model using type II
isobolographic analysis. These AEDs (except for CZP and
ETS) are clinically used in patients with partial seizures
with or without secondary generalization (Brodie and
Schachter 2001). In case of CZP, the drug is primarily used
in myoclonic and atonic seizures, whereas ETS is used in
patients with absence seizures (Brodie and Schachter
2001). Of note, experimental evidence indicates that the
studied AEDs (i.e., CZP, ETS, LEV and TGB) are ‘‘vir-
tually ineffective’’ in the mouse MES model, because the
median toxic doses (TD50 values) of these drugs were
considerably lower than their corresponding ED50 values as
determined in the mouse MES model (White et al. 2002).
Similarly, GBP has a truncated ED50 value in the mouse
MES model and thus, it was considered as virtually inef-
fective in this seizure model (Dalby and Nielsen 1997). In
case of VGB, we have documented in our pilot study that
the drug applied i.p. at doses up to 800 mg/kg did not
protect any animals against MES-induced seizures. This is
the reason that we accepted that CZP, ETS, GBP, LEV,
TGB and VGB are virtually inactive in the mouse MES-
induced seizure model, which qualifies them to be used in
the type II isobolographic analysis.
This study evaluates a potential use of 1-MeTHIQ as an
AED, especially when combined with various AEDs. This
could be an interesting treatment option when considering
the fact that 1-MeTHIQ is an endogenous molecule present
in the brain. Additionally, acute adverse effects produced
by the drugs in combination were assessed using the
chimney (motor performance) and grip-strength (skeletal
muscular strength) tests. For the drug combinations that
produced supra-additive (synergistic) interactions with
1-MeTHIQ, total brain concentrations of 1-MeTHIQ and
AEDs were measured to determine any pharmacokinetic
contribution to the observed anticonvulsant effects.
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Materials and methods
Animals and experimental conditions
All experiments were performed on adult male albino
Swiss mice (weighing 22–26 g, 7-week old) purchased
from a licensed breeder (J. Kolacz, Warszawa, Poland).
The mice were kept in colony cages with free access to
food and tap water under standardized housing conditions
(12 h/12 h light–dark cycle, light on 6:00 a.m., temperature
of 21 ± 1 C, relative humidity of 55 ± 3 %). After
7 days of adaptation to laboratory conditions, the animals
were randomly assigned to experimental groups consisting
of 8 mice. Each mouse was used only once. All tests were
performed between 9.00 a.m. and 2.00 p.m. Procedures
involving animals and their care were conducted in
accordance with the Guide for the Care and Use of Labo-
ratory Animals as adopted and promulgated by the
National Institutes of Health. Additionally, all efforts were
made to minimize animal suffering and to use only the
number of animals necessary to produce reliable scientific
data. The experimental protocols and procedures described
hereupon were approved by the First Local Ethics Com-
mittee at the Medical University in Lublin (License no.
57/2009) and Second Local Ethics Committee at the Uni-
versity of Life Science of Lublin (License no. 45/2010).
Drugs
The following drugs were used: CZP (Polfa, Warszawa,
Poland), ETS (Sigma, St. Louis, MO, USA), GBP (Parke-
Davis GmbH, Freiburg, Germany), LEV (UCB Pharma,
Braine-l’Alleud, Belgium), TGB (Sanofi Winthrop, Gen-
tilly, France), VGB (Marion Merrell S.A., Puteaux,
France), 1-MeTHIQ (gift from Dr. J. Boksa, Institute of
Pharmacology, Polish Academy of Sciences, Krakow,
Poland). 1-MeTHIQ was dissolved in 0.9 % NaCl, whereas
the AEDs were suspended in 1 % solution of Tween-80
(Sigma, St. Louis, MO, USA) in sterile saline and admin-
istered i.p. in a volume of 5 ml/kg body weight. The con-
trol animals received adequate volume of 0.9 % NaCl and
1 % solution of Tween-80 in sterile saline. Fresh drug
solutions were administered as follows: 1-MeTHIQ at
5 min (Luszczki et al. 2006a, 2009, 2010), CZP and TGB
at 15 min (Dudra-Jastrzebska et al. 2009; Luszczki et al.
2003), ETS at 45 min (Dudra-Jastrzebska et al. 2009), LEV
and GBP at 60 min (Luszczki et al. 2012), and VGB at
240 min (Luszczki et al. 2005), prior to MES, chimney and
grip-strength tests, as well as, before brain sampling for the
measurement of 1-MeTHIQ and AED concentrations. To
minimize handling effects on animals’ behavior, each
mouse received two injections, including the control
group of animals. The times to the peak of maximum
anticonvulsant effects for all AEDs were used as the ref-
erence times in all behavioral tests.
Maximal electroshock seizure test
The protective activity of 1-MeTHIQ administered alone
and six AEDs (CZP, ETS, GBP, LEV, TGB and VGB)
administered in combination with 1-MeTHIQ was evalu-
ated and expressed as median effective doses (ED50 in
mg/kg), protecting 50 % of mice against MES-induced tonic
seizures. Electroconvulsions were produced by a current
(fixed current intensity of 25 mA, maximum stimulation
voltage of 500 V, 50 Hz, 0.2 s stimulus duration) delivered
via standard auricular electrodes by a Hugo Sachs gener-
ator (Rodent Shocker, type 221, Freiburg, Germany). The
criterion for the occurrence of seizure activity was the tonic
hindlimb extension. The animals were administered with
different drug doses so as to obtain a variable percentage of
protection against MES-induced tonic seizures. In the
present study, to determine the ED50 value of 1-MeTHIQ,
the compound was administered at doses ranging between
30 and 70 mg/kg. The anticonvulsant activity of the mix-
ture of 1-MeTHIQ with the studied AEDs at the fixed ratios
of 200:1, 100:1, 50:1 and 25:1 (for the combinations of
1-MeTHIQ with CZP and TGB), 1:1, 1:2, 1:5 and 1:10 (for
the combinations of 1-MeTHIQ with ETS, GBP, LEV and
VGB) was evaluated and expressed as median effective
doses (ED50 exp values) against MES-induced seizures. In
the present study, the AEDs were administered i.p. at the
following dose ranges: 1-MeTHIQ, 25–70 mg/kg; CZP,
0.1–2 mg/kg; ETS, 30–350 mg/kg; GBP, 30–150 mg/kg;
LEV, 30–450 mg/kg; TGB, 0.1–2 mg/kg and VGB,
30–450 mg/kg. This experimental procedure has been
described in detail in our earlier studies (Luszczki et al.
2006a, b, 2009, 2012).
Type II isobolographic analysis of interaction
Isobolographic analysis of interaction is a mathematical
method allowing the precise characterization of interac-
tions between drugs in both preclinical and clinical studies
(Berenbaum 1989). This method allows determining the
interactions between drugs applied at various doses. Of
note, proportions of drugs used in two-drug mixture should
be constant and determined before experimental verifica-
tion of interactions (Tallarida 2000). This is the reason that
several fixed ratio combinations were tested isobolo-
graphically for each AED combination. In this study, we
selected four standard fixed ratio combinations of 1:1, 1:2,
1:5 and 1:10 (for the combinations of 1-MeTHIQ with
ETS, GBP, LEV and VGB) and four standard fixed ratio
combinations of 200:1, 100:1, 50:1 and 25:1 (for the
combinations of 1-MeTHIQ with CZP and TGB), which
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are routinely used when testing interactions with type II
isobolographic analysis. To perform the isobolographic
analysis of the interactions among 1-MeTHIQ and CZP,
ETS, GBP, LEV, TGB and VGB (as regards their anti-
convulsant activities against tonic seizures), the AEDs in
numerous fixed ratio combinations were administered to
animals. Subsequently, the experimentally derived ED50
exp values (±SEM) for the mixture were determined using
log-probit analysis (Litchfield and Wilcoxon 1949).
Moreover, theoretically additive ED50 add values (±SEM)
were calculated from the equation presented by Porreca
et al. (1990), as follows: ED50 add = ED50 drug 1/P1, where
P1 is the proportion of the first drug, fully effective against
tonic seizures (1-MeTHIQ) in the total amount of two-drug
mixture. It should be noted that for two-drug mixtures, the
equation presented above is true when P1 ? P2 = 1, where
P2 is the proportion of the second drug, virtually ineffective
in the MES-induced seizure test (i.e., CZP, ETS, GBP,
LEV, TGB and VGB). The proportions of AEDs in the
mixture are based on a mass quantity of AEDs (for
instance, a fixed ratio combination of 1:1 comprised equal
amounts of 1-MeTHIQ and an AED). This particular kind
of type II isobolographic analysis allows the acceptance of
mass quantity of drugs in the mixture as a basis to construct
the notation of fixed ratio combinations. For instance, for
the fixed ratio of 1:2 for 1-MeTHIQ ? ETS combination,
the proportion of 1-MeTHIQ was 1/3 = 0.3333, while the
proportion of ETS was 2/3 = 0.6666, in the total amount
of the mixture. Subsequently, the theoretical amount of
pure additive (ED50 add) mixture for the fixed ratio of 1:2 is
calculated as follows: ED50 of 1-MeTHIQ divided by P1.
Hence, ED50 add = 48.61/0.3333 = 145.83 mg/kg (Table 1).
On the other hand, the fixed ratio of 1:2 provides us with
information that the second drug used in the mixture (a
virtually ineffective AED) is administered at doses two
times higher than that for the first fully effective drug in the
mixture. A more detailed description and the theoretical
background relating to isobolographic analysis including
equations to calculate ED50 add values and their SEM have
been presented in our previous studies (Luszczki et al.
2006b, 2009). Finally, to determine the separate doses of
1-MeTHIQ and CZP, ETS, GBP, LEV, TGB and VGB in
the mixture, the ED50 exp values were multiplied by the
respective proportions of AEDs (denoted for purely addi-
tive mixture).
Measurement of total brain concentrations
of 1-MeTHIQ and AEDs
Pharmacokinetic evaluation of total brain concentrations of
1-MeTHIQ and AEDs was performed only for those
combinations of 1-MeTHIQ with AEDs that produced
synergistic interaction in the mouse MES test. Thus, the
measurement of total brain concentrations of 1-MeTHIQ
and CZP, ETS and GBP was undertaken at the drug doses
corresponding to the fixed ratios of 25:1 (1-MeTHIQ ?
CZP) and 1:10 (1-MeTHIQ ? ETS and 1-MeTHIQ ?
GBP) from the MES test, respectively. Mice were killed by
decapitation at times chosen to coincide with that sched-
uled for the MES test and whole brains were removed from
skulls, weighed, harvested and homogenized using Abbott
buffer (2:1, v/w; Abbott Laboratories, North Chicago, IL,
USA) in an Ultra-Turrax T8 homogenizer (IKA Werke,
Staufen, Germany). The brain homogenates were centri-
fuged at 10,0009g for 10 min and the supernatant samples
were analyzed either by fluorescence polarization immu-
noassay (FPIA: CZP and ETS) or by high-performance
liquid chromatography (HPLC: 1-MeTHIQ and GBP). The
supernatant samples (75 ll) were analyzed by FPIA for
CZP and ETS content using a TDx analyzer and reagents as
described by the manufacturer (Abbott Laboratories, North
Chicago, IL, USA). Control samples of CZP and ETS were
placed at the beginning and end of each carousel for ver-
ification of the calibration. For the quantitation of CZP, the
benzodiazepine assay kit was used. Total brain concen-
trations of 1-MeTHIQ were determined by HPLC using a
Dionex HPLC system (Sunnyvale, CA, USA) comprising a
quaternary pump P 580, vacuum degasser and UV–vis
detector (UVD 340S). The mobile phase consisting of
0.08 M triethylammonium phosphate buffer solution (pH
3.6) and methanol in the ratio of 85:15 (v/v) and chro-
matographic separation was achieved using a Zorbax SB-
C18 (5 lm) column (Agilent Technologies, Santa Clara,
CA, USA). Chromatography was performed at ambient
temperature using a flow ratio of 1.2 ml/min. The column
eluate was monitored at 215 nm with a sensitivity of 0.01
absorbance unit full scale (AUFS). To detect 1-MeTHIQ
concentrations, brain homogenate samples were prepared
for analysis as follows: 200 ll brain homogenate was
pipetted into 2.5 ml plastic centrifugal filter devices (Mil-
lipore Corporation, Billerica, MA, USA), to which 200 ll
of 0.08 M triethylammonium phosphate buffer solution
and 400 ll methanol were added and vortex-mixed for
1 min. After centrifugation (at 10,0009g for 10 min) the
organic layer was removed and 20 ll of the aqueous phase
was injected into the HPLC system. Quantitation was
achieved using chromatographic peak height and that was
linearly related over the range of 0.4–20 lg/ml of
1-MeTHIQ. The within-batch and between-batch precision
was\8 and\7 %, respectively. Total brain concentrations
of GBP were determined by HPLC using a Dionex HPLC
system (Sunnyvale, CA, USA) comprising a quaternary
pump P 580, vacuum degasser and UV–vis detector (UVD
340S). The mobile phase consisted of 50 mM sodium
phosphate monobasic buffer (pH 2.5), methanol and ace-
tonitrile in the ratio of 45:40:12 (v/v) and chromatographic
1654 M. Andres-Mach et al.
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separation was achieved using Hibar 125-4 Li-Chrosorb
RP-8 (5 lm) column (Merck Millipore, Darmstadt, Ger-
many). Chromatography was performed at ambient tem-
perature using a flow ratio of 1.0 ml/min. The column
eluate was monitored at 254 nm with a sensitivity of
0.01 AUFS. To detect GBP concentrations, brain homog-
enate samples were prepared for analysis as follows: 200 ll
brain homogenate was pipetted into 2.5 ml plastic cen-
trifugal filter devices (Millipore Corporation, Billerica,
MA, USA), to which 50 ll of internal standard (baclofen,
30 ll/ml) and 400 ll of acetonitrile were added and vor-
tex-mixed for 5 min. After centrifugation at 12,0009g for
10 min, 2 ml of mixture of dichloromethane:2-propanol
(1:1) was added and subsequently centrifuged at
4,0009g for 15 min. 0.1 M NaOH was added to the eluent
and the mixture was evaporated to dryness. 150 ll of
derivatizing reagent (0.35 % phenylisothiocyanate in
methanol) was added to dissolve and react with the residue.
The reaction took place at room temperature. The reaction
mixture was then evaporated to dryness. The residue was
reconstituted with 250 ll of acetonitrile and 20 ll was
injected into the HPLC system for analysis. Quantitation
was achieved using chromatographic peak height and that
was linearly related over the range of 1–100 lg/ml of GBP.
The within-batch and between-batch precision was \5 and
\6 %, respectively. Total brain concentrations of
1-MeTHIQ, ETS and GBP were expressed in lg/ml of
brain supernatants, whereas those of CZP were expressed
in ng/ml of brain supernatants as mean ± SEM of at least 8
separate brain preparations.
Chimney test
The effects of 1-MeTHIQ and the studied AEDs (CZP,
ETS, GBP, LEV, TGB and VGB) administered in com-
bination with 1-MeTHIQ (at doses corresponding to their
ED50 exp values from the MES-induced seizure test) on
motor coordination impairment were quantified with the
chimney test of Boissier et al. (1960). In the chimney test,
animals had to climb backwards up the plastic tube (3 cm
inner diameter, 30 cm length). Motor impairment was
indicated by the inability of the animals to climb backward
up the transparent tube within 60 s. Data were presented
as a percentage of animals that failed to perform the
chimney test. This experimental procedure has been
described in detail in our earlier studies (Luszczki et al.
2005, 2006a).
Grip-strength test
The effects of 1-MeTHIQ and the studied AEDs in
combination with 1-MeTHIQ (administered at doses
corresponding to their ED50 exp values from the MES-
induced seizure test) on skeletal muscular strength in mice
were quantified by the grip-strength test of Meyer et al.
(1979). The grip-strength apparatus (BioSeb, Chaville,
France) comprised a wire grid (8 cm 9 8 cm) connected to
an isometric force transducer (dynamometer). The mice
were lifted by the tails so that their forepaws could grasp
the grid. The mice were then gently pulled backward by the
tail until the grid was released. The maximal force exerted
by the mouse before losing grip was recorded. The mean of
three measurements for each animal was calculated and
subsequently, the mean maximal force of eight animals per
group was determined. The skeletal muscular strength in
mice was expressed in N (newton) as mean ± SEM of at
least eight determinations. This experimental procedure has
been described in detail in our earlier study (Luszczki et al.
2008, 2009; Zadrozniak et al. 2009).
Statistics
The ED50 value for 1-MeTHIQ and ED50 exp values (with
their respective 95 % confidence limits) for the combina-
tions of 1-MeTHIQ with CZP, ETS, GBP, LEV, TGB and
VGB at various fixed ratios in the MES-induced seizure
test were calculated by computer-assisted log-probit anal-
ysis according to Litchfield and Wilcoxon (1949). The
obtained 95 % confidence limits were transformed to SEM
as described previously (Luszczki et al. 2006b, 2009).
Statistical evaluation of isobolographic interactions was
performed by the use of Student’s t test to detect the dif-
ferences between the experimentally derived (ED50 exp)
and theoretical additive (ED50 add) values, according to
Porreca et al. (1990). The results from the grip-strength test
were statistically analyzed with one-way ANOVA fol-
lowed by the post hoc Bonferroni’s test for multiple
comparisons. The Fisher’s exact probability test was used
to analyze the results from the chimney test. Results were
considered statistically significant if P \ 0.05.
Software used
Microsoft’s Excel spreadsheet was used to perform calcu-
lations and to graphically illustrate the results in form of
isobolograms. This spreadsheet was programmed to com-
pute all calculations automatically from the log-probit
linear regression analysis according to Litchfield and
Wilcoxon (1949). The theoretically additive ED50 add val-
ues and their SEM at the various fixed ratio combinations
were also calculated with this programmed spreadsheet. All
statistical tests were performed using commercially avail-
able GraphPad Prism version 4.0 for Windows (GraphPad
Software, San Diego, CA, USA).
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Results
Effect of 1-MeTHIQ and its combination
on the anticonvulsant activity of AEDs
against MES-induced seizures in mice
1-MeTHIQ administered systemically (i.p.) exerted a clear-
cut anticonvulsant action in the mouse MES model and its
experimentally derived ED50 value was 48.61 (39.18–60.31)
mg/kg. 1-MeTHIQ in combination with CZP, at the fixed
ratios of 50:1 and 25:1, produced supra-additive (synergis-
tic) interaction (Fig. 1), whereas the two-drug combinations
at the fixed ratios of 200:1 and 100:1 were additive in the
mouse MES model (Table 1; Fig. 1). 1-MeTHIQ in com-
bination with ETS, at the fixed ratio of 1:10, exerted supra-
additive (synergistic) interaction (Fig. 1), whereas the two-
drug combinations at the fixed ratios of 1:1, 1:2 and 1:5 were
additive in the mouse MES model (Table 1; Fig. 1). Simi-
larly, the combinations of 1-MeTHIQ with TGB at the fixed
ratios of 200:1, 100:1, 50:1 and 25:1 were additive in the
mouse MES model (Table 1). Likewise, the combinations
of 1-MeTHIQ with LEV and VGB at the fixed ratios of 1:1,
1:2, 1:5 and 1:10 were additive in the mouse MES model
(Table 1; Fig. 1). Interestingly, the combinations of
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1-MeTHIQ and GBP at the fixed ratios of 1:1, 1:2, 1:5 and
1:10 were supra-additive (synergistic) in the mouse MES
model (Table 1; Fig. 1).
Total brain concentrations of 1-MeTHIQ and AEDs
in mice
The total brain concentrations were measured only for the
combinations of 1-MeTHIQ with AEDs that displayed
supra-additive interactions in the MES test. Pharmacoki-
netic study revealed that total brain CZP, ETS and GBP
concentrations were unaffected by 1-MeTHIQ (Table 2),
and inversely, CZP, ETS and GBP had no impact on total
brain concentrations of 1-MeTHIQ (Table 3), indicating
pharmacodynamic nature of interactions between
1-MeTHIQ and the studied AEDs.
Effects of 1-MeTHIQ and its combination with AEDs
on skeletal muscular strength and motor performance
in the grip-strength and chimney tests in mice
1-MeTHIQ administered systemically (i.p.) did not affect
muscular strength or motor coordination in mice (Table 4).
Moreover, for all the studied combinations of 1-MeTHIQ
with CZP, ETS, GBP, LEV, TGB and VGB, neither motor
coordination nor skeletal muscular strength was affected
(Table 4).
Discussion
The aim of this study was to characterize the type of
interactions between 1-MeTHIQ (an endogenous parkin-
sonism-preventing substance) and six various AEDs (CZP,
ETS, GBP, LEV, TGB and VGB) in the mouse MES model
using the type II isobolographic analysis. The results
indicate supra-additive (synergistic) interactions between
1-MeTHIQ and CZP, ETS and GBP at some selected fixed
ratio combinations (i.e., 50:1, 25:1 for 1-MeTHIQ ? CZP,
1:10 for 1-MeTHIQ ? ETS, and 1:10, 1:5, 1:2 and 1:1 for
1-MeTHIQ ? GBP) in the mouse MES model, and they
appear to be particularly favorable combinations from the
clinical viewpoint. Moreover, results obtained from the
estimation of total brain concentrations of 1-MeTHIQ,
CZP, ETS and GBP showed no significant changes in the
total brain concentrations of the tested drugs, suggesting
pharmacodynamic nature of interaction between
1-MeTHIQ and the AEDs in the mouse MES model. It is
noteworthy to mention that we examined only those AED
combinations that offered synergistic interactions between
1-MeTHIQ and AEDs. This is the reason that the combi-
nations of 1-MeTHIQ with CZP, ETS, and GBP were
pharmacokinetically verified in our study. Of note, the
concentrations of two drugs in mixture (i.e., 1-MeTHIQ
and an AED) were measured to exactly characterize the
type of interactions among drugs. For instance, we have
reported earlier that loreclezole (LCZ, an AED) had no
impact on total brain concentration of VPA, while the latter
AED significantly increased total brain concentrations of
LCZ and thus, the drugs in combination produced supra-
additive (synergistic) interaction in the mouse MES model
(Luszczki et al. 2006b). Hence, the evaluation of VPA
concentrations without LCZ could provide us with
incomplete data and lead to wrong conclusions. This is the
reason that in our study, the estimation of both, 1-MeTHIQ
and AEDs concentrations was performed. Moreover, in
isobolographic studies, the estimation of AED concentra-
tions in brains of experimental animals has been recom-
mended as a standard procedure because concentrations of
drugs affecting central nervous system should be evaluated
Fig. 1 a–f Isobolograms showing interactions among 1-MeTHIQ and
clonazepam (CZP), ethosuximide (ETS), gabapentin (GBP), leveti-
racetam (LEV), tiagabine (TGB) and vigabatrin (VGB) in the mouse
MES-induced seizure model. 1-MeTHIQ doses are plotted graphically
on the Y axis, whereas the doses of CZP, ETS, GBP, LEV, TGB and
VGB are plotted on the X axis (a–f). The heavy line is parallel to the
X axis, representing the ED50 value for 1-MeTHIQ administered
alone, and defines the theoretical dose-additive line for a continuum
of different fixed dose ratios. The dotted lines represent SEM values
for 1-MeTHIQ administered alone. The closed circles depict the
experimentally derived ED50 exp values for total doses of mixtures
expressed as proportions of 1-MeTHIQ and an AED that produced
median anticonvulsant effects. The SEM represents an actual
calculation of the vertical and horizontal components of the error.
a Interactions between 1-MeTHIQ and CZP. The experimental ED50
exp values for the mixture of 1-MeTHIQ ? CZP for the fixed ratios of
50:1 and 25:1 are significantly below the theoretical line of additivity,
indicating supra-additivity (*P \ 0.05 and **P \ 0.01). The fixed
ratio combinations of 200:1 and 100:1 indicate additive interactions.
b Interactions between 1-MeTHIQ and ETS. The experimental ED50
exp value for the mixture of 1-MeTHIQ ? ETS for the fixed ratios of
1:10 is significantly below the theoretical line of additivity, indicating
supra-additivity (**P \ 0.01). The fixed ratio combinations of 1:1,
1:2 and 1:5 indicate additive interactions. c Interactions between
1-MeTHIQ and GBP. The experimental ED50 exp values of the
mixture of 1-MeTHIQ ? GBP for the fixed ratios of 1:1, 1:2, 1:5 and
1:10 are significantly below the theoretical line of additivity,
indicating supra-additivity (***P \ 0.001). d Interactions between
1-MeTHIQ and LEV. The experimentally derived ED50 exp values of
the mixture of 1-MeTHIQ ? LEV for the fixed ratios of 1:1, 1:2, 1:5
and 1:10 did not significantly differ from the theoretically calculated
ED50 add values and thus, the observed interactions between
1-MeTHIQ and LEV are additive. e Interactions between 1-MeTHIQ
and TGB. The experimentally derived ED50 exp values of the mixture
of 1-MeTHIQ ? TGB for the fixed ratios of 200:1, 100:1, 50:1 and
25:1 did not significantly differ from the theoretically calculated ED50
add values and thus, the observed interactions between 1-MeTHIQ
and TGB are additive. f Interactions between 1-MeTHIQ and VGB.
The experimentally derived ED50 exp values of the mixture of
1-MeTHIQ ? VGB for the fixed ratios of 1:1, 1:2, 1:5 and 1:10 did
not significantly differ from the theoretically calculated ED50 add
values and thus, the observed interactions between 1-MeTHIQ and
VGB are additive
b
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at the site of drug action or biophase (brain tissue or
cerebrospinal fluid), where the drugs exert their anticon-
vulsant activity. For instance, we have documented that
LCZ significantly elevated the free plasma concentrations
of VPA, whereas the latter drug had no impact on total
plasma concentrations of LCZ in mice (Luszczki et al.
2006b). This is the reason that the estimation of AED
concentrations in plasma of experimental animals may
sometimes produce false information on the nature of
interaction between tested drugs (for more details see Ca-
dart et al. 2002; Luszczki et al. 2003, 2006b).
In case of combinations of 1-MeTHIQ with GBP, we
tested only the supra-additive (synergistic) combinations at
the fixed ratios of 1:1 and 1:10. Since 1-MeTHIQ had no
impact on total brain concentrations of GBP and, inversely,
GBP did not affect total brain concentrations of 1-MeTHIQ
at the fixed ratios of 1:1 and 1:10, one can indirectly accept
that the drugs in synergistic combinations at the fixed ratios
of 1:2 and 1:5 also exerted pharmacodynamic interactions
in the mouse MES model.
It should be stressed that we did not measure total brain
concentrations of 1-MeTHIQ in combination with LEV,
TGB and VGB because the observed interactions in the
mouse MES model were barely additive. From a preclinical
viewpoint, additive interactions between drugs are not as
favorable as synergistic interactions that could be advan-
tageous in patients with epilepsy. On the other hand, LEV
and VGB are considered as AEDs with ideal pharmaco-
kinetic properties, because the drugs do not bind to or do
not replace other drugs from plasma proteins, do not
undergo metabolic transformation in the liver, and do not
inhibit or activate cytochrome P450 isoenzymes (Patsalos
2004; Patsalos and Perucca 2003). Thus, it is unlikely
that 1-MeTHIQ could affect pharmacokinetic profiles of
LEV and VGB, and inversely, it is impossible that the
latter drugs could influence total brain concentrations of
Table 1 Isobolographic characterization of interactions between 1-MeTHIQ and the various AEDs in the mouse MES-induced seizure model
Drug combination Fixed ratio 1-MeTHIQexp Drugexp ED50 exp nexp ED50 add nadd Drugadd 1-MeTHIQadd
1-MeTHIQ ? CZP 200:1 45.54 0.23 45.77 ± 4.94 24 48.85 ± 5.37 22 0.24 48.61
1-MeTHIQ ? CZP 100:1 42.28 0.42 42.70 ± 4.76 8 49.09 ± 5.40 22 0.48 48.61
1-MeTHIQ ? CZP 50:1 33.66 0.67 34.33 ± 2.71* 16 49.56 ± 5.45 22 0.95 48.61
1-MeTHIQ ? CZP 25:1 31.09 1.24 32.33 ± 1.54** 24 50.48 ± 5.55 22 1.87 48.61
1-MeTHIQ ? ETS 1:1 43.95 43.95 87.90 ± 3.82 16 97.22 ± 10.69 22 48.61 48.61
1-MeTHIQ ? ETS 1:2 44.73 89.47 134.20 ± 16.48 16 145.83 ± 16.04 22 97.22 48.61
1-MeTHIQ ? ETS 1:5 38.02 190.08 228.10 ± 27.41 24 291.66 ± 32.07 22 243.05 48.61
1-MeTHIQ ? ETS 1:10 31.53 315.25 346.78 ± 23.83** 16 534.71 ± 58.80 22 486.10 48.61
1-MeTHIQ ? GBP 1:1 25.83 25.83 51.66 ± 5.85*** 32 97.22 ± 10.69 22 48.61 48.61
1-MeTHIQ ? GBP 1:2 21.78 43.56 65.34 ± 7.12*** 16 145.83 ± 16.04 22 97.22 48.61
1-MeTHIQ ? GBP 1:5 14.42 72.12 86.54 ± 12.95*** 24 291.66 ± 32.07 22 243.05 48.61
1-MeTHIQ ? GBP 1:10 13.04 130.36 143.40 ± 19.33*** 16 534.71 ± 58.80 22 486.10 48.61
1-MeTHIQ ? LEV 1:1 49.33 49.33 98.66 ± 8.58 24 97.22 ± 10.69 22 48.61 48.61
1-MeTHIQ ? LEV 1:2 47.89 95.79 143.68 ± 14.56 32 145.83 ± 16.04 22 97.22 48.61
1-MeTHIQ ? LEV 1:5 40.20 201.02 241.22 ± 24.31 32 291.66 ± 32.07 22 243.05 48.61
1-MeTHIQ ? LEV 1:10 40.01 400.12 440.13 ± 25.25 32 534.71 ± 58.80 22 486.10 48.61
1-MeTHIQ ? TGB 200:1 53.84 0.27 54.11 ± 4.75 16 48.85 ± 5.37 22 0.24 48.61
1-MeTHIQ ? TGB 100:1 44.84 0.45 45.29 ± 4.57 24 49.09 ± 5.40 22 0.48 48.61
1-MeTHIQ ? TGB 50:1 41.08 0.82 41.90 ± 2.59 16 49.56 ± 5.45 22 0.95 48.61
1-MeTHIQ ? TGB 25:1 39.37 1.58 40.94 ± 3.35 24 50.48 ± 5.55 22 1.87 48.61
1-MeTHIQ ? VGB 1:1 37.68 37.68 75.36 ± 4.96 24 97.22 ± 10.69 22 48.61 48.61
1-MeTHIQ ? VGB 1:2 42.80 85.59 128.39 ± 9.26 24 145.83 ± 16.04 22 97.22 48.61
1-MeTHIQ ? VGB 1:5 40.18 200.91 241.09 ± 21.02 24 291.66 ± 32.07 22 243.05 48.61
1-MeTHIQ ? VGB 1:10 40.18 401.81 441.99 ± 38.53 24 534.71 ± 58.80 22 486.10 48.61
Data are presented as median effective doses (ED50 in mg/kg ± SEM) protecting 50 % of animals tested against MES-induced seizures. ED50
values were either experimentally determined from the mixture of two AEDs (ED50 exp) or theoretically calculated from the equation of additivity
(ED50 add). Statistical evaluation of the data was performed using the unpaired Student’s t test with Welch’s correction. 1-MeTHIQexp, Drugexp,
1-MeTHIQadd, Drugadd are particular doses of 1-MeTHIQ and various AEDs in experimental (exp) and additive (add) mixture; n the total number
of animals at those doses whose expected anticonvulsant effects ranged between 4 and 6 probits, denoted for the experimental mixture of drugs
(nexp) and theoretically calculated (nadd) from the equation of additivity
* P \ 0.05, ** P \ 0.01 and *** P \ 0.001 versus the respective ED50 add, indicating supra-additive (synergistic) interaction
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1-MeTHIQ. In case of TGB, approx. 96 % of the drug
binds to plasma proteins (Johannessen et al. 2003). In the
liver, TGB undergoes oxidative metabolism by microsomal
cytochrome CYP3A4 isoenzyme and subsequent conjuga-
tion with glucuronic acid (Johannessen et al. 2003). Thus, it
is impossible, but not excluded, that 1-MeTHIQ and TGB
could mutually affect their pharmacokinetic profiles and
significantly change their total brain concentrations in
experimental animals.
Results presented herein also indicated that the
remaining tested combinations of 1-MeTHIQ with ETS (at
the fixed ratios of 1:1, 1:2 and 1:5) and CZP (at the fixed
ratios of 200:1 and 100:1) were additive in the mouse
MES-induced seizure model. Additionally, all the studied
combinations of 1-MeTHIQ with LEV, TGB and VGB
were additive in the mouse MES-induced seizure model
and seem to be neutral from a preclinical point of view.
To find out an explanation for the supra-additive inter-
actions of 1-MeTHIQ with CZP, ETS and GBP, one should
consider molecular mechanisms of action of the tested
AEDs. As regards GBP, the drug has its chemical structure
very similar to the inhibitory neurotransmitter gamma-
aminobutyric acid (GABA), but GBP does not act through
the brain GABA receptors (Taylor et al. 1998). GBP
interacts with a2d subunit of voltage-gated calcium chan-
nels and thus the drug reduces synaptic release of neuro-
transmitters and decreases postsynaptic calcium influx
resulting in diminished excitation (Taylor et al. 1998).
Moreover, GBP enlarges the hyperpolarization-activated
cation current (Ih) (Surges et al. 2003) and agonistically
affects ATP-dependent potassium (KATP) channels
(Bertrand et al. 2003; Cheng et al. 2006). GBP (at high
concentrations) increases the activity of the GABA-syn-
thesizing enzyme [glutamic acid decarboxylase (GAD)]
and inhibits branched-chain amino acid aminotransferase
(BCAA-T), which metabolizes cytosolic L-leucine, L-iso-
leucine, L-valine to glutamate (Goldlust et al. 1995; Hutson
et al. 1998). In case of ETS, the drug binds to the inacti-
vated state of low-threshold T-type calcium channels and
selectively inhibits pathological firing without any effect
on normal neuronal activity (Coulter et al. 1989; Gomora
et al. 2001). Moreover, ETS decreases the calcium-acti-
vated potassium current in thalamo-cortical neurons
(Coulter et al. 1989) and partially reduces the non-inacti-
vating sodium current (Leresche et al. 1998; Crunelli and
Leresche 2002). With respect to CZP mechanisms of
action, it is established that benzodiazepines (including
CZP) interact specifically with a benzodiazepine receptor
molecule to modulate allosterically the efficiency of the
inhibitory neurotransmitter GABA at GABAA receptors
(Haefely 1989; Macdonald 2002). Moreover, benzodiaze-
pines (especially, diazepam) at high concentrations also
block sodium channels voltage dependently, reducing high-
frequency repetitive firing in cultured mammalian neurons
(McLean and Macdonald 1988). The effect of diazepam to
limit repetitive firing occurred at diazepam concentrations
achieved in the treatment of status epilepticus and was not
blocked by the benzodiazepine receptor antagonist flu-
mazenil (Macdonald 2002). The similar effect on repetitive
firing can be evoked by CZP used in high doses. CZP is
classified as a partial benzodiazepine receptor agonist
(Mehta and Ticku 1989; Miller et al. 1990), which in the
Table 2 Effect of 1-MeTHIQ on total brain concentrations of AEDs
Treatment (mg/kg) FR Total brain concentration
(lg/ml) (ng/ml)
CZP (1.24) ? vehicle – 22.18 ± 1.69
CZP (1.24) ? 1-MeTHIQ
(31.09)
25:1 23.07 ± 1.83
ETS (315.3) ? vehicle – 30.31 ± 6.59
ETS (315.3) ? 1-MeTHIQ
(31.53)
1:10 36.09 ± 6.97
GBP (130.36) ? vehicle – 6.71 ± 0.55
GBP (130.36) ? 1-MeTHIQ
(13.04)
1:10 5.92 ± 0.51
GBP (25.83) ? vehicle – 2.73 ± 0.80
GBP (25.83) ? 1-MeTHIQ
(25.83)
1:1 3.22 ± 0.96
Data are presented as mean ± SEM of at least 8 separate determi-
nations. The AED concentrations were measured using either FPIA
(CZP and ETS) or HPLC (GBP). Statistical evaluation of the data was
performed using the unpaired Student’s t test. Brain tissue samples
were taken at times scheduled from the MES test
FR fixed ratio combination, vehicle, 0.9 % NaCl, CZP clonazepam,
ETS ethosuximide, GBP gabapentin
Table 3 Effect of AEDs on total brain concentrations of 1-MeTHIQ
Treatment (mg/kg) FR Total brain
concentration
(lg/ml)
1-MeTHIQ (31.09) ? vehiclea – 6.08 ± 0.49
1-MeTHIQ (31.09) ? CZP (1.24) 25:1 6.27 ± 0.43
1-MeTHIQ (31.53) ? vehiclea – 6.31 ± 0.45
1-MeTHIQ (31.53) ? ETS (315.3) 1:10 6.59 ± 0.49
1-MeTHIQ (13.04) ? vehiclea – 2.70 ± 0.42
1-MeTHIQ (13.04) ? GBP
(130.36)
1:10 3.02 ± 0.45
1-MeTHIQ (25.83) ? vehiclea – 3.70 ± 0.56
1-MeTHIQ (25.83) ? GBP (25.83) 1:1 3.88 – 0.53
Data are presented as mean ± SEM of at least 8 separate determi-
nations. The concentrations of 1-MeTHIQ were measured using the
HPLC. Statistical evaluation of the data was performed using the
unpaired Student’s t test. Brain tissue samples were taken at times
scheduled from the MES test
FR fixed ratio combination, vehiclea, 1 % solution of Tween-80 in
sterile saline, CZP clonazepam, ETS ethosuximide, GBP gabapentin
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presence of a full agonist reduces its effect acting as mixed
agonist–antagonist (Haefely 1989). In case of 1-MeTHIQ,
the compound inhibits the excitatory neurotransmitter
glutamatergic system through the blockade of NMDA
receptors as a non-competitive NMDA receptor antagonist
(Antkiewicz-Michaluk et al. 2006). At present, little is
known about the binding of 1-MeTHIQ to NMDA receptor
subunits and more advanced neurochemical studies are
required to elucidate this phenomenon.
The above-discussed mechanisms clearly indicate that
synergistic interaction between 1-MeTHIQ and GBP can
be explained through the synergistic cooperation of both
drugs in suppression of MES-induced tonic seizures. It
seems that the blockade of NMDA receptors associated
with simultaneous blockade of a2d subunit of high-voltage
activated calcium channels produced synergistic interac-
tion between drugs, independently on doses of both drugs
used in mixture. Of note, synergistic interaction between
1-MeTHIQ and GBP was reported for the drug mixture at
all the fixed ratios tested (i.e., 1:1, 1:2, 1:5 and 1:10). In
case of the combination of 1-MeTHIQ with CZP, only the
two-drug combination at the fixed ratios of 25:1 and 50:1
produced synergistic interaction in the mouse MES model.
It seems that CZP applied in high doses (i.e., 0.67 mg/kg at
the fixed ratio of 50:1 and 1.24 mg/kg at the fixed ratio
of 25:1) cooperated with 1-MeTHIQ in terms of suppres-
sion of MES-induced tonic seizures in mice. Hence,
the blockade of NMDA receptors by 1-MeTHIQ and
enhancement of GABA-ergic inhibitory neurotransmitter
system through the modulation of GABAA receptors and,
particularly, the blockade of sodium channels via benzo-
diazepine receptors considerably contribute to the sup-
pression of MES-induced seizures in mice. In case of the
combinations of 1-MeTHIQ with ETS, only the two-drug
mixture at the fixed ratio of 1:10 produced synergistic
interaction in the mouse MES model. In such a situation,
one can conclude that ETS (administered i.p. at a high dose
of 315 mg/kg that corresponded to the fixed ratio of 1:10 in
the mouse MES model) cooperated with 1-MeTHIQ. Thus,
it seems that the inhibition of T-type calcium channels and,
particularly, sodium channels by high doses of ETS in
neurons and 1-MeTHIQ-mediated blockade of NMDA
receptors suppressed MES-induced tonic seizures in
rodents. In contrast, 1-MeTHIQ did not enhance the anti-
convulsant action of TGB, VGB and LEV in the mouse
MES model. Thus, one can ascertain that the blockade of
NMDA receptors mediated by 1-MeTHIQ was insufficient
so as to cooperate with irreversible inhibition of GABA-
transaminase activity exerted by VGB (Czuczwar and
Patsalos 2001). Similarly, TGB through the inhibition of
reuptake of GABA from the synaptic clefts (Czuczwar and
Patsalos 2001) or LEV through the inhibition of synaptic
vesicle protein (SV2A) and reduction of the excitatory
neurotransmitter release (Czapinski et al. 2005) did not
cooperate with the blockade of NMDA receptors evoked by
1-MeTHIQ in terms of suppression of MES-induced tonic
seizures in mice.
Evaluation of potential acute adverse effects produced by
the AEDs in combination with 1-MeTHIQ revealed that no
significant changes in skeletal muscular strength or motor
coordination were documented in experimental animals. It
should be stressed that in our previous studies, we have
reported that VPA in combination with TGB significantly
impaired motor coordination in mice subjected to the
chimney test (Luszczki et al. 2003). Additionally, we have
documented that several various AEDs (including, CBZ,
VPA, CZP, PB, LTG, PHT, OXC and TPM) in a dose-
dependent manner reduced skeletal muscular strength in
experimental animals (Luszczki et al. 2008; Zadrozniak
et al. 2009). In contrast, sildenafil enhanced skeletal mus-
cular strength in mice challenged with the grip-strength test
(Nieoczym et al. 2010). It seems that the grip-strength test
Table 4 Effects of 1-MeTHIQ and its combination with AEDs on
skeletal muscular strength and motor performance in the grip-strength
and chimney tests in mice
Treatment (mg/kg) FR Grip-strength Motor
impairment
(N) (%)
Vehicle ? vehiclea – 0.888 ± 0.043 0
1-MeTHIQ (48.61) ? vehiclea – 0.894 ± 0.042 0
1-MeTHIQ (31.09) ? CZP
(1.24)
25:1 0.910 ± 0.044 25
1-MeTHIQ (31.53) ? ETS
(315.3)
1:10 0.865 ± 0.045 12.5
1-MeTHIQ (13.04) ? GBP
(130.36)
1:10 0.943 ± 0.039 0
1-MeTHIQ (40.01) ? LEV
(400.12)
1:10 0.911 ± 0.041 0
1-MeTHIQ (39.37) ? TGB
(1.58)
25:1 0.869 ± 0.044 12.5
1-MeTHIQ (40.18) ? VGB
(401.81)
1:10 0.865 ± 0.045 25
Results are presented as: (1) mean grip-strengths [in newton
(N) ± SEM] from the grip-strength test, assessing skeletal muscular
strength in mice; (2) percentage of animals showing motor coordi-
nation impairment in the chimney test in mice. Each experimental
group consisted of 8 animals. Statistical analysis of data from the
grip-strength test was performed with one-way ANOVA followed by
the post hoc Bonferroni’s test for multiple comparisons. The Fisher’s
exact probability test was used to analyze the results from the
chimney test. All drugs were administered i.p. at times scheduled
from the MES test and at doses corresponding to the ED50 and ED50
exp values against MES-induced tonic seizures
FR fixed ratio combination, Vehicle, 0.9 % NaCl; vehiclea, 1 %
solution of Tween-80 in sterile saline, CZP clonazepam, ETS etho-
suximide, GBP gabapentin, LEV levetiracetam, TGB tiagabine, VGB
vigabatrin
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allows the detection of some subtle changes in muscular
strength of experimental animals after administration of
tested drugs that cannot be detected in the chimney or rota-
rod tests. All the above-discussed facts clearly testify that
the behavioral tests used in this study were sensitive enough
to detect any significant changes in normal functioning of
animals after administration of 1-MeTHIQ and AEDs.
Since no significant changes were reported in the behavioral
tests in this study, we can conclude that all the tested
combinations of 1-MeTHIQ with AEDs (applied in doses
from the MES test) are safe and tolerable that could be an
additional argument when recommending 1-MeTHIQ in
combination with AEDs as the treatment options in further
clinical settings.
Finally, there has been considerable debate as to whe-
ther rational polytherapy should consist of AEDs with
similar mechanisms of action, thus allowing lower doses to
be prescribed so as to achieve anticonvulsant synergy but
without dose-related side effects, or AEDs with different
mechanisms of action so as to increase the spectrum of
anticonvulsant activity and therefore enhance seizure
control (Perucca 1995; Deckers et al. 2000; Schmidt 1996).
In the present study, the most advantageous combinations,
using the MES model, were that of 1-MeTHIQ and CZP,
ETS and GBP. The fact that 1-MeTHIQ and these AEDs
have various mechanisms of action may be important in
relation to the observed synergy. The results from the
present study confirm a hypothesis that 1-MeTHIQ had
significant effect on the anticonvulsant efficacy of various
AEDs, even if they were virtually ineffective in the mouse
MES-induced tonic seizure model. The combinations of
1-MeTHIQ with CZP, ETS and GBP need more advanced
studies, especially, in other models of epilepsy to recom-
mend their application in further clinical settings.
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